PRO 140

Drug Profile

PRO 140

Alternative Names: Humanized monoclonal antibody to CCR5; PA-14; PRO-140

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II/III HIV-1 infections
  • Phase II Graft-versus-host disease

Most Recent Events

  • 06 Oct 2017 CytoDyn announces intention to submit BLA to US FDA for HIV infections
  • 05 Oct 2017 PRO 140 receives Orphan Drug status for Graft-versus-host disease in USA
  • 30 Aug 2017 CytoDyn completes an expanded access trial for HIV-1 infections (Monotherapy) in USA (NCT02759042)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top